Systemic inflammatory indices comprising monocytes provide a clinical significance for thyroid cancer identification

包含单核细胞在内的全身炎症指标对甲状腺癌的诊断具有临床意义。

阅读:2

Abstract

Is to assess the diagnostic and prognostic role of different inflammatory indices in patients with benign and malignant thyroid nodules. The neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), derived NLR (dNLR), systemic inflammation index (SII), neutrophil to lymphocyte, platelet ratio (NLPR), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI) were assessed in150 thyroid cancer (TC) patients, 75 benign nodule patients, compared to 70 healthy controls. There was a significant difference among TC patients and control group regarding the PLR, LMR, SII, NLPR, SIRI, and AISI (p = 0.006, p < 0.001, p = 0.043,p < 0.001 p < 0.001, and p < 0.001; respectively). LMR and SIRI could efficiently differentiate malignant versus benign thyroid nodules at a cutoff of 5.2 and 0.597; respectively. LMR, PLR, SIRI, and AISI were notably associated with high-risk stratification of TC patients (p = 0.011, p = 0.035, p = 0.036, and p = 0.034; respectively). Moreover, PLR was significantly elevated in TC patients with lymph node (LN) metastasis (p = 0.010). The LMR (OR = 0.318, p < 0.001), SIRI (OR = 2.293, p = 0.001), AISI (OR = 2.714, p < 0.001), and FT4 (OR = 0.250, p < 0.001) could differentiate TC against non-TC groups. LMR, SIRI, AISI, and FT4 are independent risk factors for TC (p < 0.001, p = 0.030, p = 0.026, and p < 0.001; respectively). There was no significant impact of the assessed inflammatory indices on the disease-free survival of the patients. LMR, PLR, SII, NLPR, SIRI, and AISI could be potential supportive markers for TC diagnosis. LMR and SIRI could help in differentiating malignant versus benign thyroid nodules.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。